AbbVie looks to ADC combinations for newly licensed PD-1 x VEGF from RemeGen

The hottest class of cancer drugs from 2025 is continuing its run into the new year through a $650 million collaboration between AbbVie and RemeGen for the biotech’s PD-1 x VEGF bispecific. The deal adds AbbVie to the growing list of large pharmas buying into the class of potential Keytruda contenders.

AbbVie Inc. (NASDAQ:ABBV) licensed ex-China rights to RC148 from RemeGen Co. Ltd. (HKEX:9995; Shanghai:688331) for $650 million up front and up to $4.95 billion in milestones. The biotech is running several Phase I/II studies in China, including a study that tests the bispecific in combination with an antibody-drug conjugate (ADC). In August, it was cleared for its first U.S. Phase II trial by FDA, but that trial hasn’t started...